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Abstract
Background: The inability to produce insulin endogenously precipitates the clinical symptoms of type 1 diabetes mellitus.
However, the dynamic trajectory of beta cell destruction following onset remains unclear. Using model-based inference, the
severity of beta cell destruction at onset decreases with age where, on average, a 40% reduction in beta cell mass was
sufficient to precipitate clinical symptoms at 20 years of age. While plasma C-peptide provides a surrogate measure of
endogenous insulin production post-onset, it is unclear as to whether plasma C-peptide represents changes in beta cell
mass or beta cell function. The objective of this paper was to determine the relationship between beta cell mass and
endogenous insulin production post-onset.
Methods and Findings: Model-based inference was used to compare direct measures of beta cell mass in 102 patients
against contemporary measures of plasma C-peptide obtained from three studies that collectively followed 834 patients
post-onset of clinical symptoms. An empirical Bayesian approach was used to establish the level of confidence associated
with the model prediction. Age-corrected estimates of beta cell mass that were inferred from a series of landmark
pancreatic autopsy studies significantly correlate (p.0.9995) with contemporary measures of plasma C-peptide levels
following onset.
Conclusions: Given the correlation between beta cell mass and plasma C-peptide following onset, plasma C-peptide may
provide a surrogate measure of beta cell mass in humans. The clinical relevance of this study is that therapeutic strategies
that provide an increase in plasma C-peptide over the predicted value for an individual may actually improve beta cell mass.
The model predictions may establish a standard historical ‘‘control’’ group - a prior in a Bayesian context - for clinical trials.
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Introduction
The regulation of human metabolism is a complicated process
that has evolved to match the intermittent nature of the availability
of metabolic substrates with the constant energetic requirements
for life [1]. The dysregulation of this process may manifest itself in
multiple ways, including clinical presentation with the symptoms
of diabetes. The societal burden of diabetes is significant through
increased health care costs and reduced human productivity [2–4].
Conservative estimates predict that the number of people with
diabetes will more than double between 2000 and 2030 [5].
Reducing the overall impact of this disease requires an improved
understanding of the aetiology of diabetes.
Understanding the aetiology of type 1 diabetes mellitus is
challenging due to the inability to observe directly the events in the
human pancreas that lead to the onset of hyperglycemia [6]. While
a reduction in endogenous insulin production precipitates the
onset of hyperglycemia, it is commonly stated that the onset of
hyperglycemia occurs when 80–95% of an individual’s beta cells
are destroyed [7,8]. However, this common wisdom is based
largely on a small number of biopsy studies from individuals with
recent disease onset who died soon after diabetes onset (e.g.,
[9–11]). One might infer from this common wisdom that the
ability to enhance beta cell function or preserve the remaining beta
cells would have a limited therapeutic potential [12]. As a result,
the research effort has focused on developing prognostic tools for
identifying individual, who will develop type 1 diabetes, prior to
onset. Given the clinical importance of this question, the objective
of a recent study [13] was to test the common wisdom for the
pathophysiology of type 1 diabetes mellitus against the histopath-
ological evidence.
A meta-analysis was used to extract and assess the significance
of embedded trends within these landmark studies. The data
reported in these landmark studies provide measurements of the
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Patients included in these studies died between 0 and 117 months
following diagnosis. While beta cell mass or endogenous insulin
production are not measured directly following onset, plasma C-
peptide is used as a surrogate measure of endogenous insulin
production [16–18]. The measurement of C-peptide in a cohort of
patients with type 1 diabetes has been shown to vary non-linearly
with time following onset. These measurements suggest that
endogenous insulin production increases following onset of type 1
diabetes and then slowly declines in the subsequent years.
Therefore, inferring the beta cell mass at onset must control for
this variability in the time of beta cell mass measurement. By
limiting the analysis to a subset of patients who died within three
weeks following diagnosis, the percent reduction in beta cell mass
at onset is not fixed but varies with age [13]. This trend suggests
that, in a 20-year old individual, as little as a 40% reduction in
beta cell mass is sufficient to precipitate clinical symptoms of type 1
diabetes. As this trend is at odds with the existing model for the
natural history of the disease [19], a mathematical model, which
was created based upon physiological considerations, explains this
behavior [13]. Here, this physiology-based mathematical model
was used to predict the change - relative to age-corrected non-
diabetic controls - in beta cell mass post-onset in the entire cohort
of patients reported in these landmark studies. While changes in
plasma C-peptide may be due to either a reduction in beta cell
function or a reduction in beta cell mass, the recovery in plasma
C-peptide following onset is interpreted commonly as a recovery
in beta cell function due to therapy. To test this common
interpretation, the model predictions were used to assess whether,
following onset, the dynamics of beta cell mass correlate with the
dynamics of plasma C-peptide measurements obtained in a cohort
of more contemporary patients.
Results and Discussion
Growth of the human body is a dynamic non-linear process
where different parts of the body grow at different rates. Of
particular relevance to type 1 diabetes mellitus, body weight
changes [20] at a different rate than beta cell mass [11], as shown
in Figure 1. One possible explanation for the observed reduction
in beta cell mass at onset could be attributed to the dynamic
imbalance between the number of beta cells and the insulin
requirements for a growing body. A mathematical model was
created to test whether this explanation provides a better
representation of the data.
The rate of change in insulin in the body can be represented as
a dynamic balance between the source of insulin, which is
proportional to beta cell mass, and sinks for insulin, which are
proportional to body weight:
Rate of change in insulin~Source{Sinks: ð1Þ
This relationship can be expressed in terms of a differential
equation:
dNI
dt
~a:BCMMIN(t){kd:CI:BWt(t)
r
, ð2Þ
where NI is the number of insulin molecules in the body; a is the
maximum rate of insulin release per beta cell mass (BCM), in units
of molecules:time{1:BCM{1; BCMMIN(t) is the minimum
required beta cell mass to maintain euglycemia; kd is the rate
constant for insulin clearance from the body, in units of time{1;
CI is the plasma concentration of insulin, in units of
molecules:volume{1; BWt(t) is the body weight, in units of kg,
that changes with age, t (see Figure 1); and r is the average density
of the human body, in units of kg:volume{1. Under fasting
conditions, the source and sinks are exactly balanced such that the
rate of change of insulin is equal to zero (i.e., dNI=dt~0). Under
fasting conditions, terms in equation 2 can be rearranged to solve
for BCMMIN(t):
BCMMIN(t)~
kd:CI:BWt(age)
r:a
: ð3Þ
By defining K to be equal to (kd:CI)=(r:a), equation 3
simplifies to
BCMMIN(t)~K:BWt(t), ð4Þ
which implies that the minimum required beta cell mass is
proportional to dynamic changes in body weight, shown by the
solid curve in Figure 1.
The total beta cell mass (BCMTotal(t)) was represented as the
product of the beta cell density in the pancreas times the total
weight (volume) of the pancreas, shown as a dotted line in Figure 1.
This provides an estimate of the change in beta cell mass as a
function of age in normal individuals. In addition, the total beta
cell mass can be represented as the sum of the minimum beta cell
mass (BCMMIN) and excess, or reserve capacity, beta cell mass
(BCMExcess(t)):
BCMTotal(t)~BCMExcess(t)zBCMMIN(t): ð5Þ
Equation 5 can be rearranged, combined with equation 4, and
divided by the total beta cell mass to define the normalized excess
Figure 1. The growth rates for beta cell mass and total body
weight exhibit different dynamic trends based upon age. The
age-associated changes in total beta cell mass (dotted line) corresponds
to the product of the dynamic trends in beta cell density [11] and
volume of the pancreas [11]. The change in body weight (solid line) as a
function of age is an average value from male and female growth charts
[20]. A similar figure appears in [13] but is included here for continuity.
doi:10.1371/journal.pone.0026873.g001
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EBCM(t)~
BCMTotal(t){K:BWt(t)
BCMTotal(t)
:100: ð6Þ
This mathematical model was used to predict the ‘‘excess’’ beta
cell mass (EBCM) as a function of age t by capturing the dynamic
balance between changes in body weight and beta cell mass. The
‘‘excess’’ beta cell mass corresponds to the reduction in beta cell
mass that is required before hyperglycemia occurs. EBCM
corresponds to the ratio of insulin-deficient islets to the total
number of islets observed in the transected pancreas reported in
recent onset patients [9–11], as the size of the pancreas in recent
onset patients was unchanged relative to normal controls [13].
The resulting model prediction for EBCM as a function of age is
shown in Figure 2 (solid line). The observed reduction in beta cell
mass in pancreata obtained from the subset of recent onset patients
(i.e., died within three weeks of diagnosis) are shown for com-
parison. The parameter K was estimated to be 499 units of BCM
kg{1 (95% C.I.=458 to 605) [13]. The EBCM relationship
exhibits a similar dependence with age, as the youngest patients
exhibited an 85% reduction in beta cell mass while only a 40%
reduction was observed by the age of 20. In other words, the beta
cell mass initially grows at a faster rate relative to the whole body.
The beta cell mass plateaus while the overall body weight steadily
increases through 20 years of age. The net result of the different
growth dynamics is that the ‘‘excess’’ beta cell mass declines with
age. In addition, the mathematical model provides a prediction of
the beta cell mass required to maintain glucose homeostasis as a
function of the patient’s age t. In the following paragraphs, we will
use these predictions of the minimum required beta cell mass to
interpret plasma C-peptide levels following onset.
Comparison of beta cell mass to plasma C-peptide levels
The steady state (i.e., fasting) concentration of insulin in the
body can be obtained by rearranging Equation 3:
CI~
r:a:BCMMIN(t)
kd:BWt(t)
: ð7Þ
This relationship implies that steady state levels of insulin can be
maintained when the BCMTotal is greater than BCMMIN by
reducing the insulin production per cell (a). Conversely, CI will
decrease below fasting levels when the BCMTotal is less than
BCMMIN, as an increase in a can not be used to compensate for a
reduction in beta cell mass. To compare our model against the
plasma C-peptide data, we implicitly make a couple of
assumptions. First, an equivalent expression for Eqn 7 can be
developed for plasma C-peptide such that the observed level of
plasma C-peptide is proportional to the predicted concentration of
insulin (i.e., CC{peptide~c:CI, where c is a proportionality
constant that does not change with disease state). Second, kd for
plasma C-peptide does not depend on C-peptide concentration or
disease state. In addition, the model was originally developed using
data limited to recent onset patients (i.e., died within three weeks
of diagnosis). This was done so that the predicted value for EBCM
should match the observed changes in insulin positive islets, i.e.,
predicted EBCM minus observed EBCM should equal zero.
When considering the entire cohort, the age of the individual was
used to predict a EBCM using the corresponding values for BWt
and BCMTotal. The comparison between plasma C-peptide levels
and the predicted EBCM minus observed EBCM are both shown
as a function of time following diagnosis in Figure 3.
A predicted EBCM greater than the observed EBCM suggests
that there are less insulin deficient islets than would be expected to
maintain euglycemia given the age of the individual (i.e.,
BCMTotal is greater than BCMMIN) and suggests a recovery of
beta cell mass following onset. A predicted EBCM less than the
observed EBCM suggests that there is a further decline in beta cell
mass (i.e., BCMTotal is less than BCMMIN). The trend in the post-
mortem studies suggests a slight rise in the 10 weeks following
diagnosis followed by a progressive decline in beta cell mass. The
observed plasma C-peptide levels show a similar dynamic trend.
To establish whether changes in plasma C-peptide levels and
excess beta cell mass exhibit a statistically significant correlation,
values for plasma C-peptide levels and the predicted minus
observed excess beta cell mass obtained at the same time following
diagnosis were plotted against each other. Linear regression was
used to establish whether these two estimates of beta cell function
exhibit a positive correlation. An empirical Bayesian approach was
used to establish the statistical significance of the correlation (i.e.,
the slope is greater than 0 with greater than 95% confidence) [22].
A summary of the Markov Chain Monte Carlo results are shown
in Figure 4. These results indicate that the three Markov Chains:
1) are independent, 2) randomly sample the same region of
parameter space, 3) provide estimates of the slope and intercept
that are correlated and can not be uniquely determined, and 4)
predict that the slope is greater than zero despite the correlation.
The positive correlation between plasma C-peptide and the
difference between predicted and observed EBCM is shown in
Figure 5. As illustrated by the posterior distribution in the slope
parameter (see Figure 4B), the probability that these two quantities
exhibit a positive correlation (i.e., the slope of the dotted line is
greater than zero) is greater than 99.95%. These results also
suggest that there is a regrowth of beta cell mass following the
onset of clinical symptoms.
The use of models to aid in understanding system behavior is a
central theme in science that transcends disciplinary boundaries
[23]. In this meta-analysis of the extent of beta cell destruction in
Figure 2. Comparison between the predicted and measured
excess beta cell mass in recent onset patients. The measured
reduction in beta cell mass in 60 patients, under 20 years of age, that
died within three weeks of diagnosis of type 1 diabetes mellitus (circles
[13]) is compared against the excess beta cell mass predicted by the
physiology-based mathematical model (Equation 6 - solid curve) and a
trendline obtained by linear regression (dotted line). A similar figure
appears in [13] but is included here for continuity.
doi:10.1371/journal.pone.0026873.g002
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represented as mathematical models. The first model corresponds
to the prevailing theory that the degree of beta cell reduction at
onset is a fixed value. The second model, the physiological model,
corresponds to the idea that the observed reduction is a result of a
dynamic balance between beta cell mass and body weight.
Previously we show that the physiological model exhibits better
predictive accuracy, given the available data and the similar
complexity between the models, as each model contains a single
adjustable parameter [13]. In this work, the simplified physiological
model was used to show that age-corrected changes inbeta cellmass
correlated with changes in endogenous insulin production following
diagnosis, as an external validation of the model [21]. A correlation
between endogenous insulin production and beta cell mass has been
previouslyshowninanimalmodels[24,25]and inhumansfollowing
pancreatectomy [26,27] and islet transplantation [28,29]. To my
knowledge, this is the first analysis of data obtained during the
natural history of type 1 diabetes. Given the correlation between
age-corrected beta cell mass and plasma C-peptide following onset,
plasma C-peptide may provide a surrogate measure of beta cell
mass in humans that is adjusted for age. This work also suggests that
therapeutic strategies that provide an increase in plasma C-peptide
greater than the observed range in values for a given time following
diagnosis may actually improve beta cell mass. Longitudinal studies
that measure beta cell mass and body size in patients may be used in
the future to validate these predictions.
In summary, this physiological model suggests that clinical
presentation of the disease is not attributed solely to the
destruction of beta cell mass but is the result of a dynamic
imbalance between the production of insulin (i.e., beta cell mass)
and the size of the system (i.e., body weight). The correlation
between the model predictions and the reported changes in plasma
C-peptide suggests two points. First, the methods that were used in
these landmark studies exhibit a certain degree of accuracy in
estimating beta cell mass. By considering the trends in the data, we
are able to correct for the imprecision of the assays used. This
implies a subtle but important point. Inference of knowledge from
data is limited by the signal-to-noise ratio of the assay used to
measure a biological state (e.g., [30]). Common metrics used
to assess how well an interpretation (i.e., a model) describes
data, such as a coefficient of correlation (i.e., R2), lump the
reproducibility of an assay (i.e., the noise) together with model
inadequacy (i.e., the difference between the model and the
underlying biological signal). Conclusions drawn from studies that
evaluate the predictive potential of different biological metrics and
that do not distinguish between the underlying sources of variation
are fundamentally flawed (e.g., [27]). By using an empirical
Bayesian approach, we are able establish a level of confidence in
the biological interpretation of the data that is independent of the
underlying noise in the system. Second, the similar dynamic trends
suggest that the natural history of the disease is similar across these
studies. In part, this similarity reflects the difficulty in changing the
natural history therapeutically [14]. This dynamic trajectory in
plasma C-peptide may provide a standard historical ‘‘control’’
group for non-placebo-controlled trials, as suggested in a recent
editorial [15]. From a Bayesian perspective, this dynamic
Figure 3. Dynamic change in residual beta cell mass corresponds to the dynamic change in plasma C-peptide following onset of
type 1 diabetes. The difference between predicted and observed excess beta cell mass (right axis: x) and plasma C-peptide (left axis: square [17],
circle [18], n- children initially negative for autoantibodies at diagnosis and during follow-up [16], and ,- children positive for at least one
autoantibody [16]) shown as a function of time following clinical diagnosis of type 1 diabetes. Plasma C-peptide levels are reported as a mean + SE. A
9-point moving average of the difference in excess beta cell mass is shown for comparison (dotted line). The dynamic change in observed beta cell
mass was obtained from pancreata obtained from patients with type 1 diabetes [9–11]. The predicted beta cell mass is an estimate of the minimum
beta cell mass required to maintain glucose homeostasis.
doi:10.1371/journal.pone.0026873.g003
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prior knowledge - inferred from the clinical data obtained from 936
patients spread across multiple continents and 40+ years - for
interpreting new data. The distribution in these trajectories provides
a context for establishing a level of belief in whether a therapeutic
agent provides a significant clinical benefit. In silico model-based
inference may be particularly helpful for screening multiple
promising candidates in small non-placebo-controlled trials. Ther-
apeutic candidates that demonstrate a significant clinical benefit,
given the prior, may then be tested in larger double-blind placebo-
controlled trials,the current gold standardfor FDA approval.Sucha
staged strategy may reduce the overall cost and time associated with
approval and, ultimately, improve clinical outcomes.
Methods
In silico model-based inference was used to establish whether
changes in beta cell mass correlated with changes in endogenous
insulin production in individuals diagnosed with type 1 diabetes. Beta
cell mass was estimated from three landmark histopathology studies
that report insulin positive cells in pancreatic biopsies from patients
exhibiting symptoms of Type 1 diabetes mellitus [9–11]. Endogenous
insulin production was estimated from plasma C-peptide levels
measured in patients with type 1 diabetes [16–18]. An empirical
Bayesian approach [22] was used to establish a level of confidence
associated with the correlation between beta cell mass and plasma C-
peptide levels. The age-associated changes in total beta cell mass
(dotted line) was interpolated using the product of two cubic splines
that were fit to the dynamic trend in beta cell density [11] and to the
age-associated change in volume of the pancreas [11]. The change in
body weight (solid line) as a function of age was interpolated using a
cubic spline that was fit to the average value from male and female
growth charts [20]. Additional details regarding how the data was
analyzed are described in the following paragraphs.
Islet Histopathology Study Selection
Changes in beta cell mass in patients with type 1 diabetes were
obtained from a series of histopathology studies, which reported
insulin positive cells in pancreatic biopsies from patients exhibiting
symptoms of Type 1 diabetes mellitus. Three studies were
identified where histopathologies of the endocrine pancreas were
quantitatively reported for a group of young patients. All of the
patients were under the age of 25 and had died from primarily
diabetic ketoacidosis [9–11]. In total, 102 unique histopathology
results were included from these three studies.
C-peptide Study Selection
C-peptide is a protein that assists in the synthesis of insulin by
the beta cells and is released in the secretory granules in a 1:1
Figure 4. Markov Chain Monte Carlo summary plots for the model parameters. (A) The trace of slope and intercept parameters is shown as
a function of MCMC step. The traces for three parallel chains are shown in different colors: Chain 1 (Green), Chain 2 (Black), and Chain 3 (Red) (B)
Projection of the marginalized posterior probability density for the slope and intercept given the available data. Each point in the scatter plot
represents an individual step obtained from three parallel Markov Chains each containing 100,000 MCMC steps. The density of points is represented
by the color (yellow - highest density; blue - lowest density) and estimated using kernel density estimation. The correlation coefficient of the
parameters derived from all three Markov chains is shown above the diagonal.
doi:10.1371/journal.pone.0026873.g004
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plasma C-peptide is used as a surrogate measure of endogenous
insulin production following onset of type 1 diabetes. Three studies
were identified where longitudinal studies were used to report the
plasma C-peptide levels as a function of time following diagnosis
for type 1 diabetes [16–18]. Two studies report fasting plasma C-
peptide levels [17,18] while the third reports random measure-
ments [16]. In addition, one study stratified the reported plasma
C-peptide levels into two groups: individuals that tested positive
for at least one islet cell specific autoantibody (e.g., islet cell
antibodies (ICA), insulin autoantibodies (IAA), and glutamic acid
decarboxylase (GAD65A)) and individuals that were negative for
autoantibody expression [16]. The presence of islet cell specific
autoantibodies was a requirement for inclusion in Chaillous et al.,
while in Pozzilli et al. all of the results were reported together
irrespective of autoantibody status. The results are reported as a
mean + standard error. In total, the results for 834 patients were
included from these three studies, as summarized in Table 1.
Statistical Analysis of Age-Corrected Reduction in Beta
Cell Mass Compared to Plasma C-peptide Levels
We hypothesized that a decrease or an increase in beta cell mass
relative to the expected beta cell mass for the age of an individual
should correspond to changes in plasma C-peptide levels. The
plasma C-peptide levels are reported as aggregate values at a given
time point following diagnosis. In contrast, observations of beta
cell mass are reported for single individuals at their corresponding
time of death following diagnosis. To establish a fair comparison,
an average value for the predicted minus observed excess beta cell
mass was estimated using a nine-point moving average and
centered at the time following diagnosis (dotted line in Figure 3).
The uncertainty in the average value was also estimated using a
nine-point moving standard deviation.
An empirical Bayesian approach was used to establish the level
of confidence associated with the correlation coefficient between
these two estimates of beta cell function (i.e., the linear regression
slope), given the available data [22]. The data was weighted based
upon the sample size. A Markov chain Monte Carlo algorithm was
used to estimate the posterior distribution in the slope and
intercept of the linear regression line. An initial unbiased Gaussian
prior distribution was used to propose new steps in the Markov
chain. The prior distribution was scaled to achieve an acceptance
fraction of 0.4. The Gelman-Rubin potential scale reduction factor
was used to estimate convergence of three independent Markov
chains to the posterior distribution [31]. Posterior estimates of the
slope were obtained from the converged segments of the three
independent chains. Each of the chains contained greater than
100,000 steps following convergence. A p-value of greater than
0.95 was considered significant (i.e., greater than 95% of the steps
in the converged Markov chains exhibited a slope greater than 0).
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